Somerset-based Catalent, a provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced Tuesday it completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for innovators of advanced biotherapeutics.
On Feb. 3 Catalent agreed to acquire MaSTherCell, a company backed by Great Point Partners, SFPI-FPIM and Orgenesis Inc. for $315 million in cash.
With the addition of MaSTherCell’s unique portfolio of capabilities, technologies and related analytical services spanning both autologous and allogeneic cell therapies, Catalent said is well positioned to lead the industry with its cell and gene therapy platforms.
The acquisition adds to Catalent’s network MaSTherCell’s 25,000 square-foot clinical services facility in Gosselies, Belgium, and its 32,000 square-foot facility in Houston, Texas, which is focused on development-scale projects and scheduled to open later this quarter. Catalent said it would leverage its resources and expertise in build-outs, scale-ups and commercial manufacturing to support the expansion already underway of a 60,000 square-foot, commercial-scale cell therapy production and fill-finish facility adjacent to the existing building in Gosselies, which is scheduled to open in the fall of 2021.
Catalent financed the acquisition with the proceeds of an underwritten public offering of its common stock completed last week.